Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy.
Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.
Patients who received weekly XPro™ treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p